Black Turmeric: Neuropharmacological Claims and the Missing Anticonvulsant Evidence

This is the thinnest of the four pages in this set, and it stays that way deliberately rather than being padded to match the others. Black turmeric’s best-known traditional neurological claim — that it is “anti-epileptic” — turns out, on direct checking, to have no primary study behind it in the indexed literature at all. What genuinely exists is smaller and different: two real rodent studies on anxiety, memory and dementia, one review that has been widely mischaracterised as a study, and a real safety point about camphor that the epilepsy framing gets backwards.

Table of Contents

  1. What Is Claimed, Including “Anti-Epileptic”
  2. The Decisive Absence: No Indexed Seizure or Anticonvulsant Study
  3. Anxiety, Depression and Memory: a Real Small Study
  4. Dementia and Gut Microbiome: an Isolated Compound, Not the Herb
  5. One Research Group Defines This Entire Literature
  6. Diabetic Neuropathy: Not a Study At All
  7. Other Emerging Preclinical Work, Briefly Noted
  8. The Camphor Contradiction
  9. Practical Cautions
  10. Key Research Papers
  11. Connections

What Is Claimed, Including “Anti-Epileptic”

Black turmeric is widely described online, and in at least two indexed papers’ own background sections, as having “anticonvulsant,” “antidepressant,” “sedative” and “anti-acetylcholinesterase” effects, usually cited as a settled fact before the paper moves on to whatever it actually tested. The main hub page for this herb lists epilepsy among the claims made for it and already states plainly that there is no clinical evidence. This page goes one step further and checks whether there is even indexed preclinical evidence for the specific anticonvulsant claim — because “anti-epileptic” is repeated often enough, by people who should know the literature, that it is worth verifying directly rather than assuming it rests on something.

The Decisive Absence: No Indexed Seizure or Anticonvulsant Study

A direct, phrase-locked search of PubMed — "Curcuma caesia"[tiab] AND (epilep*[tiab] OR convuls*[tiab] OR seizure[tiab]), scoped to title and abstract so a MeSH-tree auto-expansion cannot silently substitute a different species — returns zero records. Not a small number. Zero. There is no PubMed-indexed study that tested Curcuma caesia in any seizure model, against any convulsant agent, in any animal, anywhere, as far as the indexed literature shows.

This matters because the claim is not obscure — it is one of the two or three most commonly repeated pharmacological claims for this plant, and it appears as an unreferenced background assertion inside at least two papers discussed below. The specific study the main hub page names when it discusses black turmeric’s neurological literature — Karmakar, Saha, Sarkar, Bhattacharya and Haldar, “Neuropharmacological assessment of Curcuma caesia rhizome in experimental animal models,” Oriental Pharmacy and Experimental Medicine, 2011 — was searched directly by title and author on PubMed for this page and could not be located there either. That does not prove the paper does not exist; regional and lower-visibility pharmacy journals are frequently outside PubMed’s indexing net, and the hub page’s own text already acknowledges this pattern for black turmeric generally. But it does mean this citation rule — every claim on this page backed by a PubMed-verifiable search — cannot responsibly present anticonvulsant activity as an established finding. The honest state of the evidence is: a claim repeated in secondary text, with no primary study either of us could verify. Absence of evidence is a finding in its own right, and this is a clean, checkable one: readers can run the same search themselves.

Back to Table of Contents

Anxiety, Depression and Memory: a Real Small Study

What does exist, from a Dibrugarh University group in Assam, is a real 2021 behavioural pharmacology study. Essential oil and several solvent-polarity-based fractions (hexane, ethyl acetate, methanol) of the rhizome were tested in female Wistar rats using two validated, standard behavioural assays: the elevated plus maze (anxiety) and the Morris water maze (memory), after chemically inducing hypoxia (sodium nitrite) and amnesia (scopolamine). Diazepam and galantamine — real, licensed anxiolytic and anti-dementia drugs — were used as positive controls. Doses were 200 and 400 mg/kg, given orally after an acute toxicity check.

The result: one specific fraction, labelled “fraction II” (the ethyl-acetate partition, further purified by column chromatography), showed the strongest memory-enhancing, anxiolytic and antidepressant effects, confirmed by behavioural, biochemical (acetylcholinesterase, oxidative-stress markers) and histopathological measures. The essential oil and the other two fractions showed only moderate effects.

Two things are worth stating about what this does and does not establish. First, a positive control validates that the assay is working — it does not mean the tested material matched or beat the drug in any clinically meaningful sense; the abstract does not report a head-to-head potency comparison, only that both showed activity. Second, and more important: the most active material was a specific, laboratory-purified chromatographic sub-fraction, not the essential oil, not the crude rhizome extract, and certainly not a spoonful of rhizome powder or a cup of decoction. This is the same compound- and fraction-substitution problem this doctrine flags repeatedly elsewhere — whatever “fraction II” contains, at an unspecified concentration relative to the whole rhizome, is not something a person eating or brewing this plant is consuming in an equivalent dose.

Back to Table of Contents

Dementia and Gut Microbiome: an Isolated Compound, Not the Herb

The same research group published a related 2022 study, this time isolating a single pure compound — zederone, a sesquiterpenoid, purified to 96.57% — from the rhizome, and testing it in an aluminium-induced dementia rat model (eighteen female Wistar rats, three groups of six). At 10 mg/kg, zederone improved performance on a radial eight-arm maze memory test, reduced amyloid-plaque accumulation visible by fluorescence microscopy, and shifted the gut microbiome of treated rats away from Bacteroides and toward Lactobacillus — a genuinely novel angle connecting a plant compound to the gut-brain axis in a dementia model.

This is real, specific, primary data — and it tested an isolated, purified compound at a precisely defined dose, not the rhizome. Zederone is present in C. caesia rhizome at low and variable concentration among dozens of other compounds (the 2026 toxicology study discussed on the inflammation page in this set found it only as a “minor trace constituent” in one extract, with curcumenol and curzerenone dominant instead). Nothing about a 10 mg/kg dose of 96.57%-pure zederone tells a reader what, if anything, a realistic intake of whole rhizome would deliver to the brain of a person, let alone whether it would help with dementia in a human. Small sample size (six rats per group) and a single unreplicated laboratory apply here too.

Back to Table of Contents

One Research Group Defines This Entire Literature

Worth stating plainly: both of the two genuine primary neuropharmacology studies on this species — the anxiety/depression/amnesia paper and the dementia/zederone paper — come from the same two authors (Borah and Sharma, Dibrugarh University, with a shared collaborator). No independent laboratory has yet replicated either finding. That is not a reason to dismiss the work, but it is a reason not to describe this as an established or convergent evidence base the way the cancer or antimicrobial literature, each drawing on four or more independent groups, can more reasonably claim to be.

Back to Table of Contents

Diabetic Neuropathy: Not a Study At All

A 2019 paper titled “Investigation of the utility of Curcuma caesia in the treatment of diabetic neuropathy” sounds, from the title alone, like a study of the plant in diabetic neuropathy. Reading the actual abstract shows it is a narrative review proposing a hypothesis, not a study: its own methods section states the authors reviewed “available research and review article,” plus “a number of book chapters and encyclopaedias,” to explore “several hypothesis which can be proposed” for why the plant’s already-known antioxidant, anti-inflammatory, CNS-depressant and antimicrobial properties might theoretically help in diabetic neuropathy. No new animal model, no new patient data, no diabetic neuropathy outcome of any kind was measured in this paper. Its own conclusion is written in explicitly hedged, speculative language: the plant “can be proved as a useful approach” (future tense, unproven) rather than “was shown to help.”

This is exactly the kind of citation this site’s evidence doctrine exists to catch: a title that reads as a finding, an abstract that is actually a proposal built by borrowing other studies’ unrelated results (general antioxidant and anti-inflammatory data, not diabetic-neuropathy data) and extending them by inference. It is refused here as evidence for diabetic neuropathy specifically. For readers actually looking for diabetic peripheral neuropathy management with real trial support, Alpha Lipoic Acid has a substantially larger and more direct human evidence base for this exact condition.

Back to Table of Contents

Other Emerging Preclinical Work, Briefly Noted

A few other studies touch the nervous system or its metabolic neighbours closely enough to mention without expanding this page beyond what the evidence supports:

None of these rises to a dedicated page in this set on its own; they are noted here because Grover’s 2019 review leans on exactly this kind of adjacent data (antioxidant and anti-inflammatory activity, broadly) to build its diabetic-neuropathy hypothesis, and readers deserve to see what that adjacent data actually is.

Back to Table of Contents

The Camphor Contradiction

Here is the finding this page considers its most important, and it runs directly against the marketing framing rather than supporting it. The main hub page already establishes that C. caesia essential oil is frequently camphor-dominant, and that camphor content varies enormously between samples — a 2026 genotype survey of 21 C. caesia lines found camphor ranging from 5.19% to 33.84% of the essential oil, a more than six-fold difference depending on which plant you happen to have. Camphor itself, well outside this plant’s own literature, is a well-documented convulsant in overdose: classic paediatric and adult poisoning case series and reviews describe camphor ingestion causing seizures, sometimes within minutes, and camphor poisoning is a recognised cause of emergency-department presentations for exactly this reason, including in India specifically.

Put plainly: the same plant repeatedly marketed as “anti-epileptic” — a claim with zero indexed primary evidence behind it — can be dominated, unpredictably and by more than sixfold depending on the sample, by a compound that is a recognised cause of seizures at high exposure. This is not a reason for alarm about ordinary traditional-scale use; it is a direct, evidence-based reason to be skeptical of exactly the marketing claim this page set out to check, and a concrete illustration of why point 10b of this site’s evidence doctrine — refusing unsupported claims runs in both directions — matters here specifically.

Back to Table of Contents

Practical Cautions

Back to Table of Contents

Key Research Papers

  1. Borah S, Sarkar P, Sharma HK. Analysing Curcuma caesia fractions and essential oil for neuroprotective potential against anxiety, depression, and amnesia. 3 Biotech. 2021;11(5). The real primary behavioural-pharmacology study; note the most active material was a purified sub-fraction, not the crude herb.
  2. Borah S, Sarkar P, Sharma HK. Zederone improves the fecal microbial profile in dementia induced rat model: a first report. CNS & Neurological Disorders Drug Targets. 2022;21(4). An isolated 96.57%-pure compound, not the rhizome.
  3. Grover M, Shah K, Khullar G, Gupta J, Behl T. Investigation of the utility of Curcuma caesia in the treatment of diabetic neuropathy. Journal of Pharmacy and Pharmacology. 2019;71(5). A hypothesis-generating narrative review, not a study — see the full recharacterisation above.
  4. Biswas A, Das R, Mridha P, et al. Phytochemical profiling and safety assessment of Curcuma caesia Roxb. methanolic extract in Wistar rats: an in vivo toxicological evaluation. Journal of Ethnopharmacology. 2026;366. General dosing/safety reference; zederone reported only as a minor trace constituent here, curcumenol and curzerenone dominant.
  5. Isha V, Venkatesan K, Senthil N, et al. Genetic diversity and camphor profiling of Curcuma caesia Roxb.: identification of elite genotypes and in silico prediction of gastroprotective mechanisms. Frontiers in Pharmacology. 2026;17. Source of the 5.19%–33.84% camphor-content range behind the camphor contradiction above.
  6. Ibrahim NNA, Wan Mustapha WA, Sofian-Seng NS, et al. A comprehensive review with future prospects on the medicinal properties and biological activities of Curcuma caesia Roxb. Evidence-Based Complementary and Alternative Medicine. 2023. General background and compound survey.
  7. Paw M, Gogoi R, Sarma N, et al. Study of anti-oxidant, anti-inflammatory, genotoxicity, and antimicrobial activities and analysis of different constituents found in rhizome essential oil of Curcuma caesia Roxb., collected from North East India. Current Pharmaceutical Biotechnology. 2020;21(5). Confirms camphor as a major essential-oil constituent alongside eucalyptol and epicurzerenone.
  8. Devi HP, Mazumder PB, Devi LP. Antioxidant and antimutagenic activity of Curcuma caesia Roxb. rhizome extracts. Toxicology Reports. 2015;2. The antioxidant mechanism Grover’s 2019 review leans on to build its diabetic-neuropathy hypothesis.
  9. Siegel E, Wason S. Camphor toxicity. Pediatric Clinics of North America. 1986;33(2). General reference, not species-specific: the classic clinical review documenting camphor-induced seizures.
  10. Kumar S, Kavitha TK, Angurana SK. Kerosene, camphor, and naphthalene poisoning in children. Indian Journal of Critical Care Medicine. 2019;23(12). General reference, not species-specific: contemporary Indian paediatric poisoning data, relevant given this herb’s origin and household use.

Live PubMed Search

Back to Table of Contents

Connections

Back to Table of Contents